Indications for: COMBIVIR
HIV-1 infection, in combination with other antiretroviral agents.
Adults and Children:
<30kg: not recommended. ≥30kg: 1 tab twice daily. Hepatic or renal impairment (CrCl <50mL/min): not recommended; use individual components.
Hematologic toxicity. Myopathy. Lactic acidosis and severe hepatomegaly with steatosis. Exacerbations of hepatitis B.
Risk of hematologic toxicity/bone marrow suppression; monitor CBCs esp. in advanced HIV-1 disease; interrupt dose if anemia or neutropenia occurs. Myopathy with prolonged zidovudine use. Suspend if lactic acidosis or pronounced hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Not for treating chronic HBV infection; closely monitor patients co-infected with HBV and HIV for several months after stopping treatment (discontinuing therapy may exacerbate HBV infection); if appropriate, initiate anti-hepatitis B therapy may be warranted. History of pancreatitis. Monitor for lipoatrophy; use alternatives if suspected. Women. Obesity. Elderly. Pregnancy. Nursing mothers: not recommended.
Nucleoside analogues (reverse transcriptase inhibitors).
Avoid concomitant stavudine, doxorubicin, nucleoside analogues (eg, ribavirin), sorbitol-containing products. Increased hematologic toxicity with ganciclovir, interferon alpha, ribavirin, other bone marrow suppressants or cytotoxic drugs. Monitor for treatment-associated toxicities (eg, hepatic decompensation) with interferon-alpha with or without ribavirin.
Headache, nausea, malaise, fatigue, nasal symptoms, diarrhea, cough; neutropenia, anemia, lactic acidosis, severe hepatomegaly with steatosis, myopathy, myositis, immune reconstitution syndrome, pancreatitis (discontinue if occurs), lipoatrophy.
Register pregnant patients exposed to lamivudine by calling (800) 258-4263.